Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2018-08-21
Completion Date
2027-08
Last Updated
2026-03-20
Healthy Volunteers
No
Interventions
PET/CT Scan
Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
Iodine-124
Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose. (If a holiday is present in the work week, 124I can be administered orally on Day 2, if needed).
Locations (1)
Memorial Sloan Kettering Cancer Center
New York, New York, United States